Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-09-30

Study Completion Date

2003-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI).

BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI.

MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, may prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Bacteremia Fungemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

central venous catheter bloodstream infection CVC catheter colonization local catheter site infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MBI 226

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing non-cuffed arterial and/or central venous catheterization.
* Patients able to give signed informed consent.
* Concurrent antibiotic therapy is permitted.

Exclusion Criteria

* Treatment with an experimental topical, antibacterial, or antifungal drug within the previous 30 days.
* Patients who are scheduled to receive catheters impregnated/bonded with an antimicrobial substance.
* Patients requiring arterial or central venous catheterization for less than 48 hours or longer than 28 days.
* Second or third degree burn patients.
* Patients with a suspected or known bloodstream infection or local catheter insertion site infection.
* Patients with a known allergy to adhesive tape or adhesive bandages.
* Patients with a medical condition that the Investigator believes may interfere with the safety of the patient or the intent or conduct of the study.
* Routine non-complicated post-operative CABG patients.
* The disinfection procedure for catheter insertion did not include povidone-iodine.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jim Pankovich

Role: STUDY_DIRECTOR

BioWest Therapeutics Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Omnicare Clinical Research Inc.

Lake Bluff, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

226-98-002

Identifier Type: -

Identifier Source: org_study_id